Whitney Ijem
Stock Analyst at Canaccord Genuity
(2.17)
# 2,694
Out of 4,711 analysts
82
Total ratings
34.78%
Success rate
-0.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 | $56.12 | +42.55% | 5 | Nov 19, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 | $11.56 | +237.37% | 5 | Nov 19, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 | $12.18 | +638.92% | 5 | Nov 19, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $6 → $8 | $1.85 | +332.43% | 8 | Nov 15, 2024 | |
| PASG Passage Bio | Maintains: Buy | $13 | $0.66 | +1,869.70% | 4 | Nov 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 | $44.22 | +173.63% | 7 | Nov 12, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $148 → $150 | $118.97 | +26.08% | 3 | Nov 7, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $29 → $32 | $5.74 | +457.49% | 4 | Nov 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sell | $361 → $408 | $397.27 | +2.70% | 7 | Nov 6, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $366 → $384 | $245.44 | +56.45% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $65.66 | +27.93% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 | $1.67 | +858.08% | 5 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $28 | $1.59 | +1,661.01% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $86 | $15.48 | +455.56% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.19 | +656.30% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $92.57 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $16 | $0.64 | +2,419.69% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $80
Current: $56.12
Upside: +42.55%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $39
Current: $11.56
Upside: +237.37%
Intellia Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $12.18
Upside: +638.92%
Taysha Gene Therapies
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.85
Upside: +332.43%
Passage Bio
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.66
Upside: +1,869.70%
Ultragenyx Pharmaceutical
Nov 12, 2024
Maintains: Buy
Price Target: $121
Current: $44.22
Upside: +173.63%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $118.97
Upside: +26.08%
Verve Therapeutics
Nov 6, 2024
Maintains: Buy
Price Target: $29 → $32
Current: $5.74
Upside: +457.49%
Vertex Pharmaceuticals
Nov 6, 2024
Maintains: Sell
Price Target: $361 → $408
Current: $397.27
Upside: +2.70%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $366 → $384
Current: $245.44
Upside: +56.45%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $65.66
Upside: +27.93%
Oct 18, 2024
Maintains: Buy
Price Target: $16
Current: $1.67
Upside: +858.08%
Jun 25, 2024
Maintains: Buy
Price Target: $11 → $28
Current: $1.59
Upside: +1,661.01%
May 10, 2024
Maintains: Buy
Price Target: $87 → $86
Current: $15.48
Upside: +455.56%
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $1.19
Upside: +656.30%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $92.57
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $8 → $16
Current: $0.64
Upside: +2,419.69%